You just read:

Interim sub-group analysis shows the reversal agent idarucizumab* enables rapid initiation of emergency surgery in dabigatran-treated patients

News provided by

Boehringer Ingelheim (Canada) Ltd.

Sep 08, 2015, 13:14 ET